AU2017324844B2 - Tablet compositions - Google Patents

Tablet compositions Download PDF

Info

Publication number
AU2017324844B2
AU2017324844B2 AU2017324844A AU2017324844A AU2017324844B2 AU 2017324844 B2 AU2017324844 B2 AU 2017324844B2 AU 2017324844 A AU2017324844 A AU 2017324844A AU 2017324844 A AU2017324844 A AU 2017324844A AU 2017324844 B2 AU2017324844 B2 AU 2017324844B2
Authority
AU
Australia
Prior art keywords
tablet
trifluoromethyl
pyridin
amino
triazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017324844A
Other languages
English (en)
Other versions
AU2017324844A1 (en
Inventor
Syed Altaf
Sreenivas S. Bhat
Scott Burnside
Chong-Hui Gu
Darshan PARIKH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires Servier SAS
Celgene Corp
Original Assignee
Les Laboratoires Servier SAS
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier SAS, Celgene Corp filed Critical Les Laboratoires Servier SAS
Publication of AU2017324844A1 publication Critical patent/AU2017324844A1/en
Assigned to LES LABORATOIRES SERVIER, CELGENE CORPORATION reassignment LES LABORATOIRES SERVIER Request for Assignment Assignors: AGIOS PHARMACEUTICALS, INC., CELGENE CORPORATION
Application granted granted Critical
Publication of AU2017324844B2 publication Critical patent/AU2017324844B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2017324844A 2016-09-07 2017-09-06 Tablet compositions Active AU2017324844B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662384643P 2016-09-07 2016-09-07
US62/384,643 2016-09-07
US201762535162P 2017-07-20 2017-07-20
US62/535,162 2017-07-20
PCT/US2017/050202 WO2018048847A1 (en) 2016-09-07 2017-09-06 Tablet compositions

Publications (2)

Publication Number Publication Date
AU2017324844A1 AU2017324844A1 (en) 2019-03-21
AU2017324844B2 true AU2017324844B2 (en) 2023-05-11

Family

ID=59895401

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017324844A Active AU2017324844B2 (en) 2016-09-07 2017-09-06 Tablet compositions

Country Status (16)

Country Link
US (3) US11389454B2 (https=)
EP (1) EP3509570A1 (https=)
JP (2) JP2019529534A (https=)
KR (1) KR102498693B1 (https=)
CN (2) CN109715143A (https=)
AU (1) AU2017324844B2 (https=)
BR (1) BR112019004356A2 (https=)
CA (1) CA3036053A1 (https=)
CL (1) CL2019000573A1 (https=)
CO (1) CO2019002092A2 (https=)
EC (1) ECSP19015828A (https=)
IL (1) IL265126B2 (https=)
MX (1) MX392941B (https=)
SG (1) SG11201901873PA (https=)
WO (1) WO2018048847A1 (https=)
ZA (1) ZA201901321B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CN107531675A (zh) 2015-02-04 2018-01-02 安吉奥斯医药品有限公司 治疗活性化合物及其使用方法
MX392941B (es) * 2016-09-07 2025-03-24 Celgene Corp Composiciones para comprimidos.
WO2020092894A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
WO2020092906A1 (en) * 2018-11-02 2020-05-07 Celgene Corporation Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof
WO2020092915A1 (en) * 2018-11-02 2020-05-07 Celgene Corporation Solid dispersions for treatment of cancer
WO2020239759A1 (en) * 2019-05-27 2020-12-03 Sandoz Ag Amorphous enasidenib in a stabilized form
WO2021097160A1 (en) 2019-11-14 2021-05-20 Celgene Corporation Pediatric formulations for treatment of cancer
AR126195A1 (es) * 2021-06-23 2023-09-27 Blueprint Medicines Corp Composiciones farmacéuticas de un inhibidor del receptor del factor de crecimiento epidérmico
WO2024008138A1 (zh) * 2022-07-07 2024-01-11 正大天晴药业集团股份有限公司 1,3,5-三嗪衍生物的药物组合

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015017821A2 (en) * 2013-08-02 2015-02-05 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2016053850A1 (en) * 2014-09-29 2016-04-07 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU225964B1 (en) * 1994-07-12 2008-01-28 Berwind Pharma Service Moisture barrier film coating composition, method, and coated form
TW430561B (en) * 1995-12-20 2001-04-21 Gea Farmaceutisk Fabrik As Rapid release tablet composition comprising tolfenamic acid or a pharmaceutically acceptable salt thereof as active ingredient and a method of preparing such tablet
AR016827A1 (es) * 1997-08-22 2001-08-01 Smithkline Beecham Corp PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA
IL159853A0 (en) * 2001-07-17 2004-06-20 Teva Pharma Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate
US20070010466A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
AU2010316683B2 (en) * 2009-11-09 2015-10-08 Wyeth Llc Tablet formulations of neratinib maleate
WO2012027247A2 (en) * 2010-08-23 2012-03-01 Vertex Pharmaceuticals Incorporated Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof
NZ627096A (en) 2012-01-06 2017-02-24 Agios Pharmaceuticals Inc Triazinyl compounds and their methods of use
MY185687A (en) 2013-07-11 2021-05-30 Agios Pharmaceuticals Inc N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer
WO2015018060A1 (en) 2013-08-09 2015-02-12 Agios Pharmaceuticals, Inc. Crystalline forms of therapeutically active compounds and use thereof
KR102316886B1 (ko) * 2013-08-02 2021-10-19 아지오스 파마슈티컬스 아이엔씨. 치료학적 활성 화합물 및 이의 사용방법
CN107531675A (zh) 2015-02-04 2018-01-02 安吉奥斯医药品有限公司 治疗活性化合物及其使用方法
CA3254279A1 (en) * 2015-06-03 2025-03-18 Triastek, Inc. PHARMACEUTICAL FORMS AND RELATED USES
CA2993615A1 (en) 2015-08-05 2017-02-09 Agios Pharmaceuticals, Inc. Methods of preparing 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diols and 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diamines
US10695352B2 (en) 2015-10-15 2020-06-30 Celgene Corporation Combination therapy for treating malignancies
CN108366980A (zh) 2015-10-15 2018-08-03 安吉奥斯医药品有限公司 用于治疗恶性肿瘤的组合疗法
IL298663A (en) 2015-12-04 2023-01-01 Agios Pharmaceuticals Inc Methods for treating acute myeloid leukemia characterized by the presence of a mutant allele of idh2 and the absence of a mutant allele of nras
ES2912909T3 (es) 2016-02-26 2022-05-30 Celgene Corp Enasidenib para su uso en el tratamiento de la leucemia mieloide aguda recidivante o refractaria
MX392941B (es) * 2016-09-07 2025-03-24 Celgene Corp Composiciones para comprimidos.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015017821A2 (en) * 2013-08-02 2015-02-05 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2016053850A1 (en) * 2014-09-29 2016-04-07 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use

Also Published As

Publication number Publication date
BR112019004356A2 (pt) 2019-05-28
JP2019529534A (ja) 2019-10-17
ZA201901321B (en) 2023-12-20
US20220323447A1 (en) 2022-10-13
IL265126B2 (en) 2023-12-01
IL265126A (https=) 2019-04-30
WO2018048847A1 (en) 2018-03-15
US11389454B2 (en) 2022-07-19
MX392941B (es) 2025-03-24
MX2019002697A (es) 2019-10-04
AU2017324844A1 (en) 2019-03-21
CN120501712A (zh) 2025-08-19
CA3036053A1 (en) 2018-03-15
CN109715143A (zh) 2019-05-03
ECSP19015828A (es) 2019-03-29
KR20190045199A (ko) 2019-05-02
KR102498693B1 (ko) 2023-02-10
JP7487270B2 (ja) 2024-05-20
IL265126B1 (en) 2023-08-01
CL2019000573A1 (es) 2019-07-19
NZ751112A (en) 2024-03-22
CO2019002092A2 (es) 2019-05-31
SG11201901873PA (en) 2019-03-28
JP2022191265A (ja) 2022-12-27
US20180064715A1 (en) 2018-03-08
EP3509570A1 (en) 2019-07-17
US20240335450A1 (en) 2024-10-10

Similar Documents

Publication Publication Date Title
US20240335450A1 (en) Tablet compositions
JP5017115B2 (ja) ４−（４−（３−（４−クロロ−３−トリフルオロメチルフェニル）ウレイド）−３−フルオロフェノキシ）ピリジン−２−カルボン酸を含んでなる過剰増殖性疾患の治療のための新規薬剤組成物
CN108367005B (zh) 包含酪氨酸蛋白激酶抑制剂的剂型组合物
TWI866977B (zh) 吡唑化合物之非吸濕性結晶鹽及其醫藥組合物及用途
WO2020092906A1 (en) Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof
EA049168B1 (ru) Таблетка для лечения пролиферативного заболевания
US20220017489A1 (en) Solid dispersions for treatment of cancer
US12215094B2 (en) Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
EP4058028B1 (en) Pediatric formulations for treatment of cancer
JP2023528266A (ja) 癌治療のための医薬製剤及びその調製
US20230310327A1 (en) Pharmaceutical compositions comprising ribociclib
HK40059863A (en) Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase
EA039805B1 (ru) Комбинированная терапия для лечения злокачественных опухолей

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: CELGENE CORPORATION

Free format text: FORMER APPLICANT(S): AGIOS PHARMACEUTICALS, INC.; CELGENE CORPORATION

Owner name: LES LABORATOIRES SERVIER

Free format text: FORMER APPLICANT(S): AGIOS PHARMACEUTICALS, INC.; CELGENE CORPORATION

FGA Letters patent sealed or granted (standard patent)